PMID- 30407283
OWN - NLM
STAT- MEDLINE
DCOM- 20181115
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 45
DP  - 2018 Nov
TI  - Effectiveness of Chinese herbal medicine Ping Chuan Ke Li for the management of 
      mild/moderate persistent asthma.
PG  - e12829
LID - 10.1097/MD.0000000000012829 [doi]
LID - e12829
AB  - This study assessed the effectiveness and safety of Chinese herbal medicine Ping 
      Chuan Ke Li (PCKL) for the treatment of patients with mild/ moderate persistent 
      asthma.A total of 108 eligible patients with persistent asthma were included and 
      were divided into a treatment group and a control group in this retrospective 
      study. All 108 patients underwent oral montelukast. Additionally, subjects in the 
      treatment group also received PCKL therapy. All patients in both groups were 
      treated for a total of 1 month. The primary outcome of lung function was 
      evaluated by the forced expiratory volume in one second (FEV1) and FEV1/forced 
      vital capacity (FVC). The secondary outcome of quality of life was assessed by 
      St. George's Respiratory Questionnaire (SGRQ). Moreover, adverse events (AEs) 
      were also recorded in this study. All outcome measurements were assessed after 
      1-month treatment.After 1-month treatment, patients in the treatment group did 
      not demonstrate better outcome in the improvement of lung function, measured by 
      FEV1 (P =.57, table 2), and FEV1/FVC (P =.29); and enhancement of quality of 
      life, measured by SGRQ scale (total, P =.37; symptom, P =.32; activity, P =.39; 
      impact, P =.83). In addition, no AEs differ between 2 groups.The results of this 
      study showed that Chinese herbal PCKL may not benefit for patients with 
      mild/moderate persistent asthma after 1-month treatment.
FAU - Li, Zhu-Ying
AU  - Li ZY
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Heilongjiang 
      University of Chinese Medicine.
FAU - Tian, Chun-Yan
AU  - Tian CY
AD  - Department of Graduate, Heilongjiang University of Chinese Medicine.
FAU - Wang, Xue-Hui
AU  - Wang XH
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Heilongjiang 
      University of Chinese Medicine.
FAU - Liu, Ya-Fang
AU  - Liu YF
AD  - Department of Science and Technology, Heilongjiang University of Chinese 
      Medicine, Harbin, China.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (pingchuan yiqi)
SB  - IM
MH  - Adult
MH  - Asthma/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Vital Capacity/drug effects
PMC - PMC6250504
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/11/09 06:00
MHDA- 2018/11/16 06:00
PMCR- 2018/11/09
CRDT- 2018/11/09 06:00
PHST- 2018/11/09 06:00 [entrez]
PHST- 2018/11/09 06:00 [pubmed]
PHST- 2018/11/16 06:00 [medline]
PHST- 2018/11/09 00:00 [pmc-release]
AID - 00005792-201811090-00006 [pii]
AID - MD-D-18-04806 [pii]
AID - 10.1097/MD.0000000000012829 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Nov;97(45):e12829. doi: 10.1097/MD.0000000000012829.